{"title": "Estudio multic\u00e9ntrico, abierto y a largo plazo que eval\u00faa los riesgos cardiovasculares a largo plazo", "author": null, "url": "https://ichgcp.net/es/clinical-trials-registry/NCT02232061", "hostname": "ichgcp.net", "description": "Este estudio evaluar\u00e1 si los pacientes que tuvieron un evento cardiovascular grave al iniciar el fingolimod tienen riesgo de desarrollar otros eventos cardiovas.... Registro de ensayos cl\u00ednicos. ICH GCP.", "sitename": "ichgcp.net", "date": "2014-09-02", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "Estudio multic\u00e9ntrico, abierto y a largo plazo que eval\u00faa los riesgos cardiovasculares a largo plazo\n[Novartis Pharmaceuticals](https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Novartis%20Pharmaceuticals)\nEstudio multic\u00e9ntrico, abierto y a largo plazo que eval\u00faa los riesgos cardiovasculares a largo plazo en pacientes tratados con fingolimod\nDescripci\u00f3n general del estudio\nEstado\nCondiciones\nIntervenci\u00f3n / Tratamiento\nDescripci\u00f3n detallada\nEste fue un estudio de seguridad multinacional a largo plazo. Los pacientes inscritos en el estudio FTY720D2406 que experimentaron un evento cardiovascular dentro de las 24 horas posteriores al inicio del tratamiento con fingolimod que condujo a un control durante la noche o cumplieron con los criterios de eventos adversos graves, fueron elegibles para participar en este estudio.\nLos pacientes que experimentaron un evento calificador en el estudio CFTY720D2406 comenzaron el estudio CFTY720D2409 aproximadamente 6 meses despu\u00e9s de que ocurriera el evento calificador CFTY720D2406.\nLos pacientes se sometieron a evaluaciones obligatorias cada 6 meses, incluido el ECG de 12 derivaciones y los signos vitales. Otras evaluaciones se realizaron seg\u00fan la pr\u00e1ctica habitual.\nEl objetivo principal del estudio fue estimar el riesgo cardiovascular a largo plazo de fingolimod en pacientes que experimentaron un evento cardiovascular durante el inicio del tratamiento.\nEl estudio no tiene un objetivo secundario independiente. Sin embargo, los datos de los estudios CFTY720D2409 y CFTY720D2406 se combinar\u00e1n para complementar el estudio CFTY720DD2406 y respaldar sus objetivos primario y secundario de evaluar el perfil de seguridad de fingolimod.\nLos datos agrupados se adjuntar\u00e1n a este resultado una vez que se complete el env\u00edo a la FDA.\nTipo de estudio\nInscripci\u00f3n (Actual)\nFase\n- Fase 4\nContactos y Ubicaciones\nUbicaciones de estudio\n-\nAlemania\n-\n-\nRavensburg, Alemania, 88212\n- Novartis Investigative Site\n-\n-\n-\nB\u00e9lgica\n-\n-\nGent, B\u00e9lgica, 9000\n- Novartis Investigative Site\n-\nHasselt, B\u00e9lgica, 3500\n- Novartis Investigative Site\n-\n-\n-\nItalia\n-\n-\nNapoli, Italia, 80131\n- Novartis Investigative Site\n-\n-\nCriterios de participaci\u00f3n\nCriterio de elegibilidad\nEdades elegibles para estudiar\nAcepta Voluntarios Saludables\nG\u00e9neros elegibles para el estudio\nDescripci\u00f3n\nCriterios de inclusi\u00f3n:\n- Pacientes que participaron en el estudio FTY720D2406 que experimentaron un evento cardiovascular grave durante el inicio o reinicio del tratamiento con fingolimod que condujo a un seguimiento durante la noche o cumpli\u00f3 con los criterios de gravedad.\n- Pacientes que todav\u00eda toman fingolimod despu\u00e9s del evento grave de esta primera dosis\nCriterio de exclusi\u00f3n:\n-Tratamiento con cualquier f\u00e1rmaco en investigaci\u00f3n a menos que se reciba como parte de un estudio de EM patrocinado por Novartis que dure menos de 1 mes\nPlan de estudios\n\u00bfC\u00f3mo est\u00e1 dise\u00f1ado el estudio?\nDetalles de dise\u00f1o\n- Prop\u00f3sito principal: Otro\n- Asignaci\u00f3n: N / A\n- Modelo Intervencionista: Asignaci\u00f3n de un solo grupo\n- Enmascaramiento: Ninguno (etiqueta abierta)\nArmas e Intervenciones\n|\n|\nGrupo de participantes/brazo\n|\n|\nIntervenci\u00f3n / Tratamiento\n|\n|\nExperimental: Fingolimod\nFingolimod 0,5 mg/d\u00eda comprimidos por v\u00eda oral.\n|\n|\nTableta de fingolimod 0,5 mg\nOtros nombres:\n\u00bfQu\u00e9 mide el estudio?\nMedidas de resultado primarias\n|\n|\nMedida de resultado\n|\n|\nMedida Descripci\u00f3n\n|\n|\nPeriodo de tiempo\n|\n|\nParticipantes que experimentaron al menos un evento adverso cardiovascular calificado\nPeriodo de tiempo: Dentro de los 6 meses del evento calificador hasta 64 meses\n|\n|\nLos participantes del estudio CFTY720D2406 que experimentaron un evento adverso cardiovascular calificado fueron transferidos a este estudio. Los eventos cardiovasculares calificados incluyeron, entre otros, muerte s\u00fabita inexplicable, muerte cardiovascular, infarto de miocardio (IM), IM con onda Q, accidente cerebrovascular (isqu\u00e9mico o hemorr\u00e1gico), angina inestable que requiere hospitalizaci\u00f3n, insuficiencia card\u00edaca congestiva que requiere hospitalizaci\u00f3n, bloqueo card\u00edaco completo , fibrilaci\u00f3n ventricular, torsade de pointes, emergencia hipertensiva y cualquier otra condici\u00f3n cardiovascular sospechosa que ponga en peligro la vida.\n|\n|\nDentro de los 6 meses del evento calificador hasta 64 meses\nColaboradores e Investigadores\nPatrocinador\nFechas de registro del estudio\nFechas importantes del estudio\nInicio del estudio (Actual)\nFinalizaci\u00f3n primaria (Actual)\nFinalizaci\u00f3n del estudio (Actual)\nFechas de registro del estudio\nEnviado por primera vez\nPrimero enviado que cumpli\u00f3 con los criterios de control de calidad\nPublicado por primera vez (Estimar)\nActualizaciones de registros de estudio\n\u00daltima actualizaci\u00f3n publicada (Actual)\n\u00daltima actualizaci\u00f3n enviada que cumpli\u00f3 con los criterios de control de calidad\n\u00daltima verificaci\u00f3n\nM\u00e1s informaci\u00f3n\nT\u00e9rminos relacionados con este estudio\nPalabras clave\nT\u00e9rminos MeSH relevantes adicionales\n-\n[Procesos Patol\u00f3gicos](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Pathologic%20Processes)\n-\n[Enfermedades del Sistema Nervioso](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Nervous%20System%20Diseases)\n-\n[Enfermedades del sistema inmunol\u00f3gico](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Immune%20System%20Diseases)\n-\n[Enfermedades Autoinmunes Desmielinizantes, SNC](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Demyelinating%20Autoimmune%20Diseases%2C%20CNS)\n-\n[Enfermedades Autoinmunes del Sistema Nervioso](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Autoimmune%20Diseases%20of%20the%20Nervous%20System)\n-\n[Enfermedades desmielinizantes](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Demyelinating%20Diseases)\n-\n[Enfermedades autoinmunes](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Autoimmune%20Diseases)\n-\n[Esclerosis m\u00faltiple](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Multiple%20Sclerosis)\n-\n[Esclerosis](https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Sclerosis)\n-\n[Efectos fisiol\u00f3gicos de las drogas](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Physiological%20Effects%20of%20Drugs)\n-\n[Mecanismos moleculares de acci\u00f3n farmacol\u00f3gica](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Molecular%20Mechanisms%20of%20Pharmacological%20Action)\n-\n[Agentes inmunosupresores](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Immunosuppressive%20Agents)\n-\n[Factores inmunol\u00f3gicos](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Immunologic%20Factors)\n-\n[Moduladores del receptor de fosfato de esfingosina 1](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Sphingosine%201%20Phosphate%20Receptor%20Modulators)\n-\n[Clorhidrato de fingolimod](https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Fingolimod%20Hydrochloride)\nOtros n\u00fameros de identificaci\u00f3n del estudio\n- CFTY720D2409\nPlan de datos de participantes individuales (IPD)\n\u00bfPlanea compartir datos de participantes individuales (IPD)?\nDescripci\u00f3n del plan IPD\nNovartis se compromete a compartir con investigadores externos calificados el acceso a datos a nivel de paciente y documentos cl\u00ednicos de respaldo de estudios elegibles. Estas solicitudes son revisadas y aprobadas por un panel de revisi\u00f3n independiente sobre la base del m\u00e9rito cient\u00edfico. Todos los datos proporcionados se anonimizan para respetar la privacidad de los pacientes que han participado en el ensayo de acuerdo con las leyes y regulaciones aplicables.\nLa disponibilidad de datos de este ensayo est\u00e1 de acuerdo con los criterios y el proceso descritos en\nhttps://www.clinicalstudydatarequest.com/\nInformaci\u00f3n sobre medicamentos y dispositivos, documentos del estudio\nEstudia un producto farmac\u00e9utico regulado por la FDA de EE. UU.\nEstudia un producto de dispositivo regulado por la FDA de EE. UU.\nEsta informaci\u00f3n se obtuvo directamente del sitio web\n[clinicaltrials.gov](https://clinicaltrials.gov) sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comun\u00edquese con [register@clinicaltrials.gov](mailto:register@clinicaltrials.gov). Tan pronto como se implemente un cambio en [clinicaltrials.gov](https://clinicaltrials.gov), tambi\u00e9n se actualizar\u00e1 autom\u00e1ticamente en nuestro sitio web. .\nEnsayos cl\u00ednicos sobre Esclerosis m\u00faltiple\n-\nNCT06042244A\u00fan no reclutando\n[Entrenamiento con ejercicios multimodales para reducir la fragilidad en personas con esclerosis m\u00faltiple](https://ichgcp.net/es/clinical-trials-registry/NCT06042244)Esclerosis m\u00faltiple | Fragilidad\n-\nNCT06032468ReclutamientoCarrera | Esclerosis m\u00faltiple | Enfermedad de Parkinson\n-\nNCT06028776Reclutamiento\n-\nNCT06025903Reclutamiento\n-\nNCT06025968A\u00fan no reclutandoEsclerosis m\u00faltiple | Insomnio\n-\nNCT06021561ReclutamientoEsclerosis m\u00faltiple\n-\nNCT06020937A\u00fan no reclutando\n-\nNCT06019611A\u00fan no reclutandoEsclerosis m\u00faltiple | Enfermedades autoinmunes | Trastorno desmielinizante\n-\nNCT06017726A\u00fan no reclutandoEsclerosis m\u00faltiple | Resistencia a la insulina\n-\nNCT06016309Reclutamiento\nEnsayos cl\u00ednicos sobre Fingolimod\n-\nNCT05962177A\u00fan no reclutando\n-\nNCT05718947Reclutamiento\n-\nNCT05688436Reclutamiento\n-\nNCT05516303Reclutamiento\n-\nNCT05415579A\u00fan no reclutando\n[Registro de Enfermedades Desmielinizantes del Sistema Nervioso Central para Pacientes con Medicina Tradicional China (DATE-TCM)](https://ichgcp.net/es/clinical-trials-registry/NCT05415579)Enfermedades Desmielinizantes del Sistema Nervioso Central (DDC)\n-\nNCT05307731ReclutamientoDiabetes Mellitus, Tipo 2\n-\nNCT05123703Reclutamiento\n-\nNCT05112484A\u00fan no reclutando\n-\nNCT05060354ReclutamientoEsclerosis m\u00faltiple | Saludable\n-\nNCT05042635A\u00fan no reclutando", "language": null, "image": null, "pagetype": "website", "links": ["https://ichgcp.net/es", "#", "https://ichgcp.net/de", "https://ichgcp.net/", "https://ichgcp.net/es", "https://ichgcp.net/fr", "https://ichgcp.net/it", "https://ichgcp.net/pt", "https://ichgcp.net/ru", "https://ichgcp.net/es/guidance-for-industry-investigator-responsibilities-protecting-the-rights-safety-and-welfare-of-study-subjects", "https://ichgcp.net/es/guidance-for-the-notification-of-serious-breaches-of-gcp-or-the-trial-protocol", "https://ichgcp.net/es/national-statement-on-ethical-conduct-in-human-research-2007-updated-2018-nhmrc-australia", "https://ichgcp.net/es/ministerial-ordinance-on-good-clinical-practice-for-drugs-pharmaceuticals-and-medical-devices-agency-japan", "https://ichgcp.net/es/ich-e-group-of-guidelines", "https://ichgcp.net/es/cro-list", "https://ichgcp.net/es/clinical-trials-registry", "https://ichgcp.net/es/eu-clinical-trials-registry", "https://ichgcp.net/es/pharma-list", "https://ichgcp.net/es/labs", "https://ichgcp.net/es/service-companies", "https://ichgcp.net/es/events", "https://ichgcp.net/es/clinical-trials-registry/publications", "https://ichgcp.net/es/clinical-trials-registry/researchers", "https://ichgcp.net/es/cra-jobs", "https://ichgcp.net/es/publications", "https://ichgcp.net/es/news", "https://ichgcp.net/clinical-trials-registry/NCT02232061", "https://telegram.me/share/url?url=https://ichgcp.net/es/clinical-trials-registry/NCT02232061&text=", "https://twitter.com/intent/tweet?url=https://ichgcp.net/es/clinical-trials-registry/NCT02232061", "https://ichgcp.net/es", "https://ichgcp.net/es/clinical-trials-registry", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Novartis%20Pharmaceuticals", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Multiple%20Sclerosis", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Fingolimod", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Fingolimod", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Novartis%20Pharmaceuticals", "https://ichgcp.net/es/clinical-trials-registry/research/list?term=multiple%20sclerosis%2C%20fingolimod%2C%20adult%2C%20FTY720%2C%20inflammatory%20disease%2C%20demyelination%2C%20auto-inflammatory%20disease%2C%20relapsing-remitting%20MS%2C%20CFTY720D2406", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Pathologic%20Processes", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Nervous%20System%20Diseases", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Immune%20System%20Diseases", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Demyelinating%20Autoimmune%20Diseases%2C%20CNS", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Autoimmune%20Diseases%20of%20the%20Nervous%20System", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Demyelinating%20Diseases", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Autoimmune%20Diseases", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Multiple%20Sclerosis", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Sclerosis", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Physiological%20Effects%20of%20Drugs", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Molecular%20Mechanisms%20of%20Pharmacological%20Action", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Immunosuppressive%20Agents", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Immunologic%20Factors", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Sphingosine%201%20Phosphate%20Receptor%20Modulators", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Fingolimod%20Hydrochloride", "https://clinicaltrials.gov", "mailto:register@clinicaltrials.gov", "https://clinicaltrials.gov", "https://ichgcp.net/es/clinical-trials-registry/NCT06042244", "https://ichgcp.net/es/clinical-trials-registry/NCT06032468", "https://ichgcp.net/es/clinical-trials-registry/NCT06028776", "https://ichgcp.net/es/clinical-trials-registry/NCT06025903", "https://ichgcp.net/es/clinical-trials-registry/NCT06025968", "https://ichgcp.net/es/clinical-trials-registry/NCT06021561", "https://ichgcp.net/es/clinical-trials-registry/NCT06020937", "https://ichgcp.net/es/clinical-trials-registry/NCT06019611", "https://ichgcp.net/es/clinical-trials-registry/NCT06017726", "https://ichgcp.net/es/clinical-trials-registry/NCT06016309", "https://ichgcp.net/es/clinical-trials-registry/NCT05962177", "https://ichgcp.net/es/clinical-trials-registry/NCT05718947", "https://ichgcp.net/es/clinical-trials-registry/NCT05688436", "https://ichgcp.net/es/clinical-trials-registry/NCT05516303", "https://ichgcp.net/es/clinical-trials-registry/NCT05415579", "https://ichgcp.net/es/clinical-trials-registry/NCT05307731", "https://ichgcp.net/es/clinical-trials-registry/NCT05123703", "https://ichgcp.net/es/clinical-trials-registry/NCT05112484", "https://ichgcp.net/es/clinical-trials-registry/NCT05060354", "https://ichgcp.net/es/clinical-trials-registry/NCT05042635", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Center%2Bfor%2BIndustrial%2BTechnological%2BDevelopment%2Bof%2BSpain", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=SeeCure%2BLLC", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Universidad%2Bdel%2BZulia", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Cairo%2BUniversity", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Assistance%2BPublique%2B-%2BH%25C3%25B4pitaux%2Bde%2BParis", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Orphanetics%2BPharma%2BEntwicklungs%2BGmbH", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Pediatric%2BOrthopaedic%2BSociety%2Bof%2BNorth%2BAmerica", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Assiut%2BUniversity", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Universidade%2Bde%2BLisboa%252C%2BPortugal", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Mayo%2BClinic", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Novartis%2BPharmaceuticals", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Jos%25C3%25A9phine%2BSOLTANI%252C%2BCardiology%2Bdepartment%252C%2BVersailles%2BHospital", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Pfizer", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Kaneka%2BAmericas%2BHolding%2BInc.", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=GlaxoSmithKline", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Medtronic%2BSurgical%2BTechnologies", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=M.D.%2BAnderson%2BCancer%2BCenter", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=European%2BSociety%2Bof%2BHuman%2BReproduction%2Band%2BEmbryology", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=AstraZeneca", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=National%2BCancer%2BInstitute%2B%2528NCI%2529", "https://ichgcp.net/es/clinical-trials-registry/research/browse/spns_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Esophageal%2BResection%2BCandidates", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Stage%2BI%2BGallbladder%2BCancer%2BAJCC%2Bv8", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Prostate%2BCancer", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Depression", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=HIV%2BInfections", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Carcinoma%252C%2BAdrenal%2BCortical", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Obesity", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Cushing%2527s%2BSyndrome%2BI", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Ultrasound%2BEvaluation", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Pain", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Colon%2BMalignant%2BTumor", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Stroke", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Coronary%2BArtery%2BDisease", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Post-traumatic%2BAnosmia", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Breast%2BCancer", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Malignant%2BNeoplasm%2Bof%2BRespiratory%2Band%2BIntrathoracic%2BOrgan%2BCarcinoma", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Ankle%2BArthroplasty", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Hypertension", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Postneoadjuvant%2BTherapy%2BStage%2BI%2BGastric%2BCancer%2BAJCC%2Bv8", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Asthma", "https://ichgcp.net/es/clinical-trials-registry/research/browse/cond_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Alpelisib%2B150%2BMG%2BOral%2BTablet%2B%255BPiqray%255D", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Transplant%2B2%2BMelphalan", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Brimonidine%2Btartrate%2Bophthalmic%2Bsolution%2B0.025%2525%2B%2528n%2B%253D%2B56%2529", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Oral%2BGlucose%2BGel", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Paclitaxel", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Cisplatin", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Capecitabine", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Injectafer", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=MK-8521%2B100%25CE%25BCg", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Carboplatin", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Pilocarpine%2B1.25%2525%2BEye%2Bdrop", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Dexamethasone", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Prednisone", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Cyclophosphamide", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Teicoplanin%2BSandoz%2B200%2Bmg%2Bpowder%2Band%2Bsolvent%2Bfor%2Bsolution%2Bfor%2Binjection%2Bor%2Binfusion%2Bor%2Boral%2Bsolution.", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=20mg%2BAzilsartan%2BTablets", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Bevacizumab", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Valacyclovir%2Barrow", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Docetaxel", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Gemcitabine", "https://ichgcp.net/es/clinical-trials-registry/research/browse/intr_alpha_all", "https://ichgcp.net/es/cro-list/country/armenia", "https://ichgcp.net/es/cro-list/country/brazil", "https://ichgcp.net/es/cro-list/country/burundi", "https://ichgcp.net/es/cro-list/country/el_salvador", "https://ichgcp.net/es/cro-list/country/estonia", "https://ichgcp.net/es/cro-list/country/ireland", "https://ichgcp.net/es/cro-list/country/italy", "https://ichgcp.net/es/cro-list/country/jordan", "https://ichgcp.net/es/cro-list/country/kenya", "https://ichgcp.net/es/cro-list/country/morocco", "https://ichgcp.net/es/cro-list/country/qatar", "https://ichgcp.net/es/cro-list/country/suriname", "https://ichgcp.net/es/cro-list/country/thailand", "https://ichgcp.net/es/cro-list", "https://ichgcp.net/es/cro-list/country/guinea/company/sgs", "https://ichgcp.net/es/cro-list/country/guinea", "https://ichgcp.net/es/clinical-trials-registry/research/browse/cond_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/cond_cat", "https://ichgcp.net/es/clinical-trials-registry/research/browse/ord_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/intr_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/intr_cat", "https://ichgcp.net/es/clinical-trials-registry/research/browse/diet_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/diet_cat", "https://ichgcp.net/es/clinical-trials-registry/research/browse/spns_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/spns_cat", "https://ichgcp.net/es/clinical-trials-registry/research/browse/locn_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/locn_cat", "https://ichgcp.net/es", "https://ichgcp.net/es/guidance-for-industry-investigator-responsibilities-protecting-the-rights-safety-and-welfare-of-study-subjects", "https://ichgcp.net/es/guidance-for-the-notification-of-serious-breaches-of-gcp-or-the-trial-protocol", "https://ichgcp.net/es/national-statement-on-ethical-conduct-in-human-research-2007-updated-2018-nhmrc-australia", "https://ichgcp.net/es/ministerial-ordinance-on-good-clinical-practice-for-drugs-pharmaceuticals-and-medical-devices-agency-japan", "https://ichgcp.net/es/guideline-for-the-notification-of-serious-breaches-of-regulation-eu-no-536-2014", "https://ichgcp.net/es/cro-list", "https://ichgcp.net/es/pharma-list", "https://ichgcp.net/es/labs", "https://ichgcp.net/es/service-companies", "https://ichgcp.net/es/cra-jobs", "https://ichgcp.net/es/clinical-trials-registry", "https://ichgcp.net/es/eu-clinical-trials-registry", "https://ichgcp.net/es/publications", "https://ichgcp.net/es/news", "https://ichgcp.net/about-us-our-mission", "https://ichgcp.net/es/sitemap", "https://ichgcp.net/es/contact-us", "https://ichgcp.net/es/feed", "/privacy", "/disclaimer", "https://ichgcp.net/da/clinical-trials-registry/NCT02232061", "https://ichgcp.net/de/clinical-trials-registry/NCT02232061", "https://ichgcp.net/clinical-trials-registry/NCT02232061", "https://ichgcp.net/es/clinical-trials-registry/NCT02232061", "https://ichgcp.net/fr/clinical-trials-registry/NCT02232061", "https://ichgcp.net/it/clinical-trials-registry/NCT02232061", "https://ichgcp.net/hu/clinical-trials-registry/NCT02232061", "https://ichgcp.net/nl/clinical-trials-registry/NCT02232061", "https://ichgcp.net/no/clinical-trials-registry/NCT02232061", "https://ichgcp.net/pl/clinical-trials-registry/NCT02232061", "https://ichgcp.net/pt/clinical-trials-registry/NCT02232061", "https://ichgcp.net/fi/clinical-trials-registry/NCT02232061", "https://ichgcp.net/sv/clinical-trials-registry/NCT02232061", "https://ichgcp.net/cs/clinical-trials-registry/NCT02232061", "https://ichgcp.net/ru/clinical-trials-registry/NCT02232061", "https://ichgcp.net/ja/clinical-trials-registry/NCT02232061", "https://ichgcp.net/zh/clinical-trials-registry/NCT02232061", "https://ichgcp.net/ko/clinical-trials-registry/NCT02232061", "https://ichgcp.net/pdf/privacy_cookies_policy.pdf", "https://ichgcp.net/pdf/terms_of_service.pdf", "https://ichgcp.net/pdf/privacy_cookies_policy.pdf", "https://ichgcp.net/pdf/terms_of_service.pdf"]}